Eli Lilly and Co. has purchased the exclusive rights from biotech firm MacroGenics to develop teplizumab, a molecule that has potential for treating Type 1 diabetes, in a bid to further expand its diabetes drug pipeline. Teplizumab, which researchers say could protect insulin-producing beta cells of the pancreas, is currently undergoing late-stage trials to treat patients with recent-onset Type 1 diabetes.

Related Summaries